Nianzeng Xing

Supplementary Table S3 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer

Hongtao Song, Tong Lü, Donghui Han, Jiayu Zhang et autres

Supplementary Table 3: Antibodies for Flow Cytometry

Supplementary Table S1 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer

Hongtao Song, Tong Lü, Donghui Han, Jiayu Zhang et autres

Supplementary Table 1: The clinical information of patients and TMA

Supplementary Table S5 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer

Hongtao Song, Tong Lü, Donghui Han, Jiayu Zhang et autres

Supplementary Table 5: Human primers for qRT-PCR analysis

Supplementary Table S4 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer

Hongtao Song, Tong Lü, Donghui Han, Jiayu Zhang et autres

Supplementary Table 4: Antibodies for Western Blot and immunofluorescence staining

Supplementary Table S6 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer

Hongtao Song, Tong Lü, Donghui Han, Jiayu Zhang et autres

Supplementary Table 6: The clinical information of scRNA-seq data and the numbers of cells in each sample

Supplementary Table S2 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer

Hongtao Song, Tong Lü, Donghui Han, Jiayu Zhang et autres

Supplementary Table 2: Genotyping Primers and expected band size

Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01

Arun Azad, Neeraj Agarwal, Andrew J. Armstrong, Eva Hellmis et autres

Poly(ADP-ribose) polymerase (PARP) inhibitor plus androgen receptor pathway inhibitor (ARPI) is approved for selected patients with metastatic castration-resistant prostate cancer. Saruparib (AZD5305) is a new-generation PARP inhibitor that selectively inhibits and traps PARP1. EvoPAR-Prostate01 is a Phase III, 2-cohort, randomized, double-blind, placebo-controlled, …

au, us, jp, tr, cn, br, ca (code pays fourni par la source)

Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial

Alicia K Morgans, Kunhi Parambath Haresh, Mindaugas Jievaltas, David Olmos et autres

us, in, lt, es, lv, cn, de, ch, ca (code pays fourni par la source)

Quercetin's antitumor effect in bladder cancer: Synergistic regulation of gut microbiota and l-serine metabolic pathway

Zhao Zhai, Feiya Yang, Ru Feng, Hao Zhang et autres

Quercetin is a bioflavonoid that is abundant and easy to extract, and has beneficial effects such as anti-cancer, anti-inflammatory, and antioxidant properties. We have demonstrated that oral administration of quercetin in an animal model inhibits bladder cancer (BCa), with inhibition rates of …

cn (code pays fourni par la source)

Efficacy and safety of darolutamide and ADT in patient subgroups by baseline comorbidities and concomitant medications: ARANOTE post hoc analyses.

Fred Saad, K. P. Haresh, E. Vjaters, David Olmos et autres

178 Background: Darolutamide (DARO) + androgen deprivation therapy (ADT) significantly improved radiological progression-free survival (rPFS) vs placebo (PBO) + ADT (HR 0.54, 95% CI 0.41–0.71; P<0.0001) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) in the phase 3 ARANOTE (NCT04736199) trial, …

ca, in, lv, es, cn, ch, us, it (code pays fourni par la source)

TulmiSTAR-01: A phase I/II dose optimization study of tulmimetostat in combination with luxdegalutamide versus standard of care (SOC) in patients (pts) with progressive metastatic castrate-resistant prostate cancer (mCRPC).

Andrew J. Armstrong, E. Castro Marcos, Stephane Oudard, Xin Gao et autres

TPS301 Background: Prostate cancer is the second leading cause of cancer death in men, and mCRPC remains difficult to treat due to acquired resistance to androgen receptor pathway inhibitors (ARPIs). Preclinical studies implicate enhancer of zeste homolog 2 (EZH2) in mediating resistance …

us, es, fr, cn, ch, au (code pays fourni par la source)

A phase II study of luxdegalutamide in combination with abiraterone in adult patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Rana R. McKay, Benjamin Garmezy, Michael Thomas Schweizer, Nianzeng Xing et autres

TPS275 Background: Androgen deprivation therapy (ADT) remains the cornerstone of mHSPC treatment, yet patients with high-volume disease experience poorer outcomes and faster progression. Combining agents that target androgen receptor (AR) signaling at multiple steps has been demonstrated to improve overall survival (OS) …

us, gb, cn, de, es (code pays fourni par la source)